Uniqure NV (NASDAQ:QURE) CEO Matthew C. Kapusta sold 39,169 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the sale, the chief executive officer now owns 439,764 shares in the company, valued at approximately $9,551,674.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Matthew C. Kapusta also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, January 4th, Matthew C. Kapusta sold 21,690 shares of Uniqure stock. The stock was sold at an average price of $19.87, for a total value of $430,980.30.

Shares of Uniqure NV (NASDAQ:QURE) opened at $20.78 on Tuesday. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure NV has a 1-year low of $4.72 and a 1-year high of $27.19. The firm has a market capitalization of $684.06, a PE ratio of -7.07 and a beta of 0.09.

Several brokerages have weighed in on QURE. Zacks Investment Research downgraded Uniqure from a “hold” rating to a “sell” rating in a report on Saturday, February 24th. HC Wainwright set a $35.00 price target on Uniqure and gave the stock a “buy” rating in a report on Tuesday, February 20th. BidaskClub downgraded Uniqure from a “buy” rating to a “hold” rating in a report on Saturday. Janney Montgomery Scott began coverage on Uniqure in a report on Wednesday, January 3rd. They set a “buy” rating and a $25.00 price target on the stock. Finally, ValuEngine upgraded Uniqure from a “sell” rating to a “hold” rating in a report on Monday, January 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $20.75.

Several large investors have recently added to or reduced their stakes in QURE. SG Americas Securities LLC acquired a new position in shares of Uniqure during the 4th quarter worth about $119,000. Ellington Management Group LLC acquired a new position in shares of Uniqure during the 4th quarter worth about $237,000. Goldman Sachs Group Inc. acquired a new position in shares of Uniqure during the 4th quarter worth about $373,000. Virtus Fund Advisers LLC acquired a new position in shares of Uniqure during the 4th quarter worth about $389,000. Finally, OxFORD Asset Management LLP acquired a new position in shares of Uniqure during the 3rd quarter worth about $399,000. 43.98% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/uniqure-nv-qure-ceo-matthew-c-kapusta-sells-39169-shares-of-stock/1948302.html.

About Uniqure

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.